1. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. (23rd August 2018) Authors: Staehler, M; Motzer, R J; George, D J; Pandha, H S; Donskov, F; Escudier, B; Pantuck, A J; Patel, A; DeAnnuntis, L; Bhattacharyya, H; Ramaswamy, K; Zanotti, G; Lin, X; Lechuga, M; Serfass, L; Paty, J; Ravaud, A Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2098 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. (20th October 2018) Authors: Gross-Goupil, M; Kwon, T G; Eto, M; Ye, D; Miyake, H; Seo, S I; Byun, S -S; Lee, J L; Master, V; Jin, J; DeBenedetto, R; Linke, R; Casey, M; Rosbrook, B; Lechuga, M; Valota, O; Grande, E; Quinn, D I Journal: Annals of oncology Issue: Volume 29:Number 12(2018) Page Start: 2371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗